Indore Online Journal

NSCLC Market Size in the 7MM is expected to grow by 2034 | DelveInsight

 Breaking News
  • No posts were found

NSCLC Market Size in the 7MM is expected to grow by 2034 | DelveInsight

April 16
17:25 2024
NSCLC Market Size in the 7MM is expected to grow by 2034 | DelveInsight

DelveInsight’s “NSCLC Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the NSCLC, historical and forecasted epidemiology as well as the NSCLC market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the NSCLC Market Research Report

  • The increase in NSCLC Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the NSCLC market is anticipated to witness growth at a considerable CAGR.
  • The leading NSCLC Companies working in the market include EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, and others.
  • Promising NSCLC Pipeline Therapies in the various stages of development include M1774, C-TIL051, ACY-241 + Nivolumab, 18F-AraG, Nivolumab + Plinabulin, JIN-A02, FWD1509 MsOH, Osimertinib, BMS-813160, Sutetinib Maleate Capsule, Sotorasib and Tarloxotinib, RH324, AMG 794, Capmatinib, H002, VIC-1911, MYTX-011, ITIL-306, Adagrasib, DS-1062a, NEO-201 in combination with pembrolizumab, PT-112, PBF-1129, REGN2810, RMC-4630, CLN-081, LN-145, IPH5201 + durvalumab + standard chemotherapy, and others.
  • April 2024: Daiichi Sankyo announced a study of Phase 2 clinical trials for Trastuzumab deruxtecan. This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease recurrence or progression during/after at least one regimen of prior anticancer therapy (second line or later) that must have contained a platinum-based chemotherapy drug.
  • April 2024: Galecto Biotech AB announced a study of Phase 1 & 2 clinical trials for GB1211 and Atezolizumab. This study is an open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).
  • April 2024: Summit Therapeutics announced a study of Phase 3 clinical trials for  Ivonescimab (SMT112 or AK112) Injection. A Randomized, Double-blind, Multi-center, Phase III Clinical Study of Ivonescimab (SMT112 or AK112) or Placebo Plus Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)

 

Discover which therapies are expected to grab the NSCLC Market Share @ NSCLC Market Outlook

 

NSCLC Overview 

 NSCLC stands for Non-Small Cell Lung Cancer, which is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. Unlike small cell lung cancer (SCLC), which tends to grow and spread more quickly, NSCLC generally grows at a slower rate and has different treatment options.

 

NSCLC Epidemiology Insights

The epidemiology section of NSCLC offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

  • Total Incident Cases of NSCLC Patients
  • Total Incident Cases of NSCLC Patients by Histology
  • Total Diagnosed Cases of NSCLC Patients by Stages
  • Total NSCLC Cases of Patients by Genetic Mutation/Biomarkers
  • Total Treated Cases of NSCLC Patients by Line of Therapies

 

Download the report to understand which factors are driving NSCLC Epidemiology trends @ NSCLC Epidemiological Insights

 

NSCLC Drugs Market

The NSCLC Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying NSCLC signaling in NSCLC are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

NSCLC Treatment Market Landscape

The NSCLC treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of NSCLC has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about NSCLC treatment guidelines, visit @ NSCLC Treatment Market Landscape

 

NSCLC Market Outlook

The report’s outlook on the NSCLC market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing NSCLC therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed NSCLC drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed NSCLC market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

NSCLC Drugs Uptake

The drug chapter of the NSCLC report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to NSCLC.

 

Major NSCLC Companies

Several NSCLC Companies working in the market include EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, and others.

 

Learn more about the FDA-approved drugs for NSCLC @ Drugs for NSCLC Treatment

 

Scope of the NSCLC Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • NSCLC Companies-  EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, and others.
  • NSCLC Pipeline Therapies- M1774, C-TIL051, ACY-241 + Nivolumab, 18F-AraG, Nivolumab + Plinabulin, JIN-A02, FWD1509 MsOH, Osimertinib, BMS-813160, Sutetinib Maleate Capsule, Sotorasib and Tarloxotinib, RH324, AMG 794, Capmatinib, H002, VIC-1911, MYTX-011, ITIL-306, Adagrasib, DS-1062a, NEO-201 in combination with pembrolizumab, PT-112, PBF-1129, REGN2810, RMC-4630, CLN-081, LN-145, IPH5201 + durvalumab + standard chemotherapy, and others.
  • NSCLC Market Dynamics: NSCLC Market Drivers and Barriers
  • NSCLC Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about NSCLC Drugs in development @ NSCLC Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of NSCLC

3. Competitive Intelligence Analysis for NSCLC

4. NSCLC: Market Overview at a Glance

5. NSCLC: Disease Background and Overview

6. Patient Journey

7. NSCLC Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. NSCLC Unmet Needs

10. Key Endpoints of NSCLC Treatment

11. NSCLC Marketed Products

12. NSCLC Emerging Therapies

13. NSCLC: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of NSCLC

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories